MetaVia has linked its GLP-1/glucagon receptor agonist to reductions in liver fat and body weight in a phase 1 trial.

The aim is to reduce the biopharma’s R&D workforce by more than 35% compared with 2025 levels, with the associated cost ...

Vivoryon Therapeutics has regained the China rights to its kidney disease prospect as the German biotech’s cash reserves ...

Evommune has agreed to pay $30 million to China’s Hinova Pharmaceuticals to get stuck into a niche of preclinical molecular ...

Charles River Laboratories’ virtual control group (VCG) database will be used in a toxicology study run by French biopharma ...

AbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase ...

Ultragenyx is laying off 20% of its workforce and axing drug development programs to cut its annual R&D budget to half of the ...

Originally, Rhythm licensed the melanocortin 4 receptor (MC4R) candidate, known at the time as LB54640, from LG for $80 ...

Teva has given up on a key trial of one of its original lineup of innovative medicines. | Teva has given up on a key trial of ...

AbbVie has scrapped a phase 2 solid tumor drug after deciding that the monoclonal antibody was unlikely to best the current ...

Pfizer has axed a phase 2 pulmonary arterial hypertension program on business grounds, dealing a setback to a long-running ...

Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental ...